| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $13.4M | — | +2.6% |
| SG&A Expense | $6.9M | — | +40.7% |
| Operating Income | -$20.3M | — | -13.0% |
| Net Income | -$18.3M | — | -10.1% |
| EPS (Basic) | -$0.10 | — | +16.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $55.2M | +80.0% | +34.4% |
| Short-term Investments | $139.5M | -21.7% | +94.9% |
| Current Assets | $195.7M | -6.7% | +57.6% |
| Total Assets | $205.2M | -6.6% | +56.1% |
| Current Liabilities | $10.3M | -26.4% | -31.0% |
| Total Liabilities | $18.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.3M | — | -30.7% |
| Capital Expenditures | $82K | — | +355.6% |
| Investing Cash Flow | $38.4M | — | +231.6% |
| Financing Cash Flow | $3.4M | — | +512.9% |
| Free Cash Flow | -$17.4M | — | -31.2% |
| -11.7% |
| Stockholders' Equity | $186.5M | -5.2% | +69.1% |